What is the purpose of this trial?
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with pembrolizumab. TIL as a single-therapy will be evaluated with LN-145 only.
Start Date: 12/19/2018
End Date: 04/30/2020
Last Updated: 12/20/2018
Study HIC#: 2000023142